Relevant studies have shown that excessive interleukins are the causative factor of many inflammatory diseases. Anti-interleukin-1β (IL-1β) antibodies can quickly and specifically block the binding of IL-1β to its receptor, thereby blocking the occurrence of inflammation.  

The company's Genakumab is a Class I new drug for therapeutic biological products. It is an anti-IL-1β antibody drug produced through genetic engineering technology. Genakumab is currently in the clinical research stage for indications such as gouty arthritis, systemic juvenile idiopathic arthritis, and connective tissue disease-related interstitial lung disease. In terms of acute gouty arthritis, the main part of the Phase III clinical trial has been completed and the domestic NDA has been submitted. The main efficacy has reached the expected goal. Clinical data show that Genakumab can effectively relieve patients' pain and significantly reduce the risk of recurrence; in terms of systemic juvenile idiopathic arthritis (SJIA), Phase IIb is being enrolled; in terms of connective tissue disease-related interstitial lung disease, Phase II clinical work has now begun with relevant preclinical studies have shown that Genakumab can take effect quickly and maintain efficacy for a long time, and delay the progression of pulmonary fibrosis.